99results about How to "Improve tumor killing ability" patented technology

The invention relates to an engineered immune cell, and the engineered immune cell expresses (i) a chimeric receptor, and (ii) exogenous CCL3, CCL4 and/or CCL5. The invention further provides application of the engineered immune cell to treatment of cancers, infections or autoimmune diseases. Compared with a traditional engineered immune cell, the engineered immune cell provided by the invention has the remarkably improved tumor killing activity.

The invention relates to a gel injection combining a molecular targeted drug and a cytotoxic drug. The gel injection comprises a small molecular targeted drug, a traditional cytotoxic drug, a temperature-sensitive material, a solvent and pharmaceutical excipients, wherein the temperature-sensitive material is selected from poloxamer, polylacticacid-polyethylene glycol-polylactic acid or polyglycolide lactide-polyethylene glycol-polyglycolide lactide and the like; the solvent is selected from water, brine salt or 5% glucose aqueous solution and the like, the prepared gel injection can be injected intratumorally or peritumorally, the anti-tumor effect is obvious, and the side effects are fewer.

The invention discloses a metal organic framework composite nanomaterial with targeting property and pH responsiveness as well as a preparation method and application of the metal organic framework composite nanomaterial. The metal organic framework composite nanomaterial is prepared from protein-loaded ZIF-8 metal organic framework nano-particles, calcium carbonate structures wrapping the ZIF-8 nano-particles and aptamers fixed to calcium carbonate structures. The preparation method is simple and convenient to operate, and damage to protein activity is avoided. The composite nano material provided by the invention has good protein loading capacity and targeting performance, and can gradually release contents in a low pH environment. The metal organic framework composite nanomaterial disclosed by the invention can also target T cells to increase the number of intracellular anti-tumor active substances, and can be developed into a novel anti-tumor biological therapy.

The invention discloses a construction method of a chimeric antigen receptor double-negative T cell. The construction method comprises the following steps: according to characteristics of CD3<+>/CD4<->/CD8<->double-negative T cell, selecting the purified CD3<+>/CD4<->/CD8<->double-negative T cell in vitro, and utilizing the synergistic principle of multiple cell factor signal channels and a TCR signal channel to screen out an in-vitro culture scheme suitable for activation and virus transfection of the double-negative T cell. The in-vitro culture scheme can quickly and controllably activate the double-negative T cell, expresses the specific chimeric antigen receptor on the double-negative T cell through a lentiviral transfection technology at high efficiency, preparing a CAR-DN-T cell, enables the CAR-DN-T cell to specifically identify the tumor cell corresponding to the chimeric antigen receptor, promotes the CAR-DN-T cell to be further activated and proliferated, and quickly kills and wounds the tumor cell. According to the construction method disclosed by the invention, the prepared CAR-DN-T cell is from homologous variants of other healthy donators, so that the preparation of the cell gets rid of limitation of the current illness situation of a patient, the cell can be prepared on a large scale in advance, and the patient can be subjected to low-dosage re-transfusion treatment for multiple times according to the clinical diagnosis result at any time.

The present invention provides a therapeutic agent comprising isolated recombinant oncolytic adenoviruses and immune cells and uses thereof. The therapeutic agent comprises: a tfirst composition, wherein the first composition comprises a first active ingredient located in a first pharmaceutically acceptable carrier, wherein the first active component comprises an isolated recombinant oncolytic adenovirus, the recombinant oncolytic adenovirus is a selective replication type oncolytic adenovirus, and a coding sequence of exogenous shRNA capable of inhibiting PDL1 expression in tumor cells is integrated in a genome of the recombinant oncolytic adenovirus; and a second composition wherein the second composition comprises a second active ingredient located in a second pharmaceutically acceptable carrier, the second active ingredient comprising T cell receptor modified immune cells or chimeric antigen receptor modified immune cells. According to the invention, the oncolytic adenovirus and the immune cells are combined for use to realize a synergistic treatment effect, and the administration mode enriches the treatment mode and treatment means of tumor treatment.

The present invention relates to an engineered immune cell, which is capable of expressing a chimeric antigen receptor, an exogenous Flt3L gene and a DLL1 gene, and optionally an XCL1 and/or XCL2 gene. The invention also provides the use of the engineered immune cell in the treatment of cancer, infection or autoimmune disease. Compared with a traditional CAR cell, the engineered immune cell has the advantage that the tumor killing activity is remarkably improved.

The present invention relates to: —use of a 2,3-dihydroimidazo[1,2-c]quinazoline compound, or of a pharmaceutical composition containing same, as a sole active agent, or of a combination of a) said compound or a pharmaceutical composition containing said compound and b) one or more further active agents, for the preparation of a medicament for the treatment or prophylaxis of cancer; —combinations of a) said compound and b) one or more further active agents; —a pharmaceutical composition comprising said compound as a sole active agent for the treatment of breast cancer; —a pharmaceutical composition comprising a combination of a) said compound and b) one or more further active agents; —use of biomarkers involved in the modification of Bel expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN for predicting the sensitivity and/or resistance of a cancer patient to said compound and providing a rationale-based synergistic combination as defined herein to increase sensitivity and/or to overcome resistance; and —a method of determining the level of a component of one or more of Bcl expression, HER family expression and/or activation, PIK3CA signaling and/or loss of PTEN.

The present invention relates to a method for identifying a substance capable of disrupting an interaction between (i) a herpes simplex virus (HSV) ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, and (ii) proliferating cell nuclear antigen (PCNA) or a homologue thereof, or a derivative thereof. The method comprises: (a) providing an HSV ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, as a first component; (b) providing PCNA, or a homologue thereof, or a derivative thereof, as a second component; (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and (d) determining whether the substance disrupts the interaction between the first and second components.

The invention provides a fourth-generation CAR-T cell and an application thereof. The fourth-generation CAR-T cell expresses a chimeric antigen receptor specifically binding to an antigen, a secretoryIL-7 and an NFAT regulatory CCL19,wherein the signal peptide of the IL-7 is an IL-10 signal peptide; and a promoter of the CCL19 is an NFAT regulatory promoter. According to the invention, the original signal peptide of the IL-7 is changed into the signal peptide of T cell secretory protein IL-10, and the NFAT regulatory promoter is adopted as the promoter of CCL19, so that the CAR-T cell can secrete the IL-7 to the outside of the cell and conditionally express the CCL19, the proliferation of the CAR-T cell is promoted, immune cells are recruited to the inside of tumors to the greatest extent, and the anti-tumor efficacy of the CAR-T is obviously improved.

The invention relates to a pH-responsive nano preparation based on a click reaction and a preparation method and an application thereof. The pH-responsive nano preparation based on the click reactionis formed by that a hydrophobic carboxylic acid small molecule antitumor drug coupled with the heparinized heparin polysaccharide by a Schiff base reaction and the click reaction to form an amphipathic conjugate, and the amphipathic conjugate is subjected to self-assembly in a water body to obtain the nano preparation. The click reaction is simple and environmentally friendly, the reaction conditions are mild, the product is easy to separate, and the yield is high. After the pH-responsive nano-preparation reaches the acidic microenvironment of the tumor, the Schiff base bond is broken, and a carboxylic acid derivative intermediate is obtained. Further rearrangement results in a prototype of a small molecule of carboxylic acid, which can well avoid the influence of other groups on the activity of the carboxylic acid molecule. In addition, the pH-responsive nano preparation can physically entrap the hydrophobic anti-tumor drug, and obtains a physical drug-loaded pH-responsive nano preparation to achieve synergistic anti-tumor effect.

The invention discloses an EGFR (epidermal growth factor receptor)-specific chimeric antigen receptor and application thereof. The EGFR-specific chimeric antigen receptor comprises a transmembrane signal region, an extracellular recognition region, a hinge region, a transmembrane region and an intracellular signal transduction region, which are connected in sequence. A CAR-T with the surface modified by the EGFR-specific chimeric antigen receptor has a strong tumor-specific antigen activation effect, a cytokine secretion function and a tumor-killing ability for triple negative breast cancer; the in-vitro killing efficiency is more than 90% under a low effector-to-target ratio; animal experiments verify the remarkable effective inhibitory effect of the CAR-T, the CAR-T has a remarkable tumor suppressive effect in in-vivo experiments, and accordingly, it is indicated that the CAR-T of the EGFR-specific chimeric antigen receptor has high applicability to the triple negative breast cancer.

The invention discloses a copper composite based intelligent nanometer material and a preparation method and antitumor application thereof, and belongs to the fields of a nanometer material and preparation thereof. A copper composite is synthesized firstly, the copper composite and near infrared fluorescent dyes are loaded to an organic phase change material together, and a light control intelligent nanometer material being uniform to disperse and good in light heat efficiency can be prepared. The nanometer material can cause DNA injury and apoptosis through light control target cell nucleus,an EMT process is restrained, the transfer ability of tumor cells is destroyed, and the copper composite based intelligent nanometer material is hopeful to be used for antitumor research.